{"protocolSection": {"identificationModule": {"nctId": "NCT00623714", "orgStudyIdInfo": {"id": "0000-065"}, "secondaryIdInfos": [{"id": "065"}, {"id": "2008_509"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Induced Sputum Study (0000-065)", "officialTitle": "A Randomized, Placebo-Controlled, Crossover Study to Assess the Effects of Inhaled Fluticasone on Markers of Inflammation After Allergen Challenge in Patients With Allergic Asthma"}, "statusModule": {"statusVerifiedDate": "2015-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-02-11", "studyFirstSubmitQcDate": "2008-02-25", "studyFirstPostDateStruct": {"date": "2008-02-26", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-24", "resultsFirstSubmitQcDate": "2010-05-24", "resultsFirstPostDateStruct": {"date": "2010-06-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-15", "lastUpdatePostDateStruct": {"date": "2015-05-05", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. The results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 13, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Arm 1", "type": "EXPERIMENTAL", "description": "study medication + Pbo", "interventionNames": ["Drug: Comparator: fluticasone", "Drug: Placebo"]}, {"label": "Arm 2", "type": "EXPERIMENTAL", "description": "Pbo + study medication", "interventionNames": ["Drug: Comparator: fluticasone", "Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Comparator: fluticasone", "description": "Two puffs, of 250 \u00b5g each, will be administered to each patient to obtain a 500-\u00b5g dose at each prespecified time point. A total of five (5) doses (500 \u00b5g) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.", "armGroupLabels": ["Arm 1", "Arm 2"], "otherNames": ["fluticasone"]}, {"type": "DRUG", "name": "Placebo", "description": "Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.", "armGroupLabels": ["Arm 1", "Arm 2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)", "timeFrame": "Baseline and 24 hours post allergen challenge"}], "secondaryOutcomes": [{"measure": "Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)", "timeFrame": "Baseline and 24 hours post allergen challenge"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has a history of mild to moderate persistent allergic asthma for at least 6 months with typical symptoms, including cough, wheezing, and shortness of breath, is clinically stable and has no history of recent respiratory tract infection within 3 weeks of the start of the study\n* Patient, aside history of asthma, is judged to be in good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests.\n* Patient is able to perform reproducible pulmonary function test.\n* Patient has an allergic response to house dust mite allergen, demonstrates a positive early and late phase response to an inhaled allergen challenge (as defined by a bronchoconstrictive response)\n* Patient is a nonsmoker for at least 12 months. Patients must have less than or equal to 10 pack years of smoking to be included. (10 pack years = one pack per day for 10 years.) Patients who have discontinued smoking for at least 10 months may be enrolled at the discretion of the investigator\n* Patient is willing to avoid strenuous physical activity (i.e., strenuous or unaccustomed weight lifting, running, bicycling, etc.) for 72 hours prior to each visit when laboratory safety tests are obtained and 48 hours prior to allergen challenge\n\nExclusion Criteria:\n\n* Patient has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or poses additional risk to the patient by their participation in the study\n* Patient has taken oral corticosteroids within 8 weeks or inhaled corticosteroids/nasal corticosteroids within 4 weeks of screening and/or during the study\n* Patient has a history of stroke, chronic seizures, or major neurological disorder\n* Patient has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory (other than asthma), or genitourinary abnormalities or diseases, or has a history of neoplastic disease\n* Patient is unable to refrain from or anticipates the use of any medication other than the ones permitted in this study, including prescription and non-prescription drugs or herbal remedies prior to administration of the initial dose of study drug, throughout the study (including washout intervals between treatment periods), until the poststudy visit\n* Patient consumes excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages per day or \\>21 drink equivalents per week.\n* Patient consumes excessive amounts, defined as greater than 6 servings of coffee, tea, cola, or other caffeinated beverages per day", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Inclusion\n\n* Mild/moderate allergic asthma\n* Allergic to house, dust, mite allergen\n* Early and late allergic response to inhaled allergen challenge\n\nRandomized sequence of treatments including 500 \u03bcg fluticasone or placebo in treatment periods 1 \\& 2. Treatment was twice a day (b.i.d.) for total of 5 doses over 3-day period.", "recruitmentDetails": "First Patient Entered: 28-Jan-2008\n\nLast Patient, Last Visit: 05-Mar-2009\n\n1 site", "groups": [{"id": "FG000", "title": "Placebo Then Fluticasone", "description": "Days 1-2 Placebo twice a Day (b.i.d.) + Day 3 Placebo single dose, Days 1-2 500 \u00b5g Fluticasone b.i.d. + Day 3 500 \u00b5g Fluticasone single dose"}, {"id": "FG001", "title": "Fluticasone Then Placebo", "description": "Days 1-2 500 \u00b5g Fluticasone b.i.d. + Day 3 500 \u00b5g Fluticasone single dose, Days 1-2 Placebo b.i.d. + Day 3 Placebo single dose"}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "All Patients", "description": "All Randomized Patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "13"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "25.9", "lowerLimit": "21", "upperLimit": "43"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "4"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)", "populationDescription": "All Patients as Treated", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline and 24 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Days 1-2 Placebo b.i.d. + Day 3 Placebo single dose"}, {"id": "OG001", "title": "Fluticasone", "description": "Days 1-2 500 \u00b5g Fluticasone b.i.d. + Day 3 500 \u00b5g Fluticasone single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.57", "lowerLimit": "1.37", "upperLimit": "4.84"}, {"groupId": "OG001", "value": "0.87", "lowerLimit": "0.46", "upperLimit": "1.64"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.011", "pValueComment": "1-sided, alpha = 0.05", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis performed on log-transformed fold change from baseline and results were back-transformed for reporting.", "paramType": "Geometric Mean Fold Difference", "paramValue": "0.34", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.16", "ciUpperLimit": "0.70"}]}, {"type": "SECONDARY", "title": "Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)", "populationDescription": "All Patients as Treated", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pg/mL", "timeFrame": "Baseline and 24 hours post allergen challenge", "groups": [{"id": "OG000", "title": "Placebo", "description": "Days 1-2 Placebo b.i.d. + Day 3 Placebo single dose"}, {"id": "OG001", "title": "Fluticasone", "description": "Days 1-2 500 \u00b5g Fluticasone b.i.d. + Day 3 500 \u00b5g Fluticasone single dose"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2.11", "lowerLimit": "1.41", "upperLimit": "3.17"}, {"groupId": "OG001", "value": "0.85", "lowerLimit": "0.57", "upperLimit": "1.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.002", "pValueComment": "1-sided, alpha = 0.05", "statisticalMethod": "ANOVA", "statisticalComment": "Analysis performed on log-transformed fold change from baseline and results were back-transformed for reporting.", "paramType": "Geometric Mean Fold Difference", "paramValue": "0.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.26", "ciUpperLimit": "0.63"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse experiences were collected from the time the consent is signed through the 14 day follow up period after all treatment periods were completed", "description": "AE s were assessed by clinical evaluation including vital signs, physical examination, medical history, clinical laboratory safety assessment (hematology, chemistry, urinalysis), and ECG at timepoints specified in the study. Patients were queried at each visit for any adverse experiences since the previous visit.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Days 1-2 Placebo b.i.d. + Day 3 Placebo single dose", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 5, "otherNumAtRisk": 13}, {"id": "EG001", "title": "Fluticasone", "description": "Days 1-2 500 \u00b5g Fluticasone b.i.d. + Day 3 500 \u00b5g Fluticasone single dose", "seriousNumAffected": 0, "seriousNumAtRisk": 13, "otherNumAffected": 6, "otherNumAtRisk": 13}], "otherEvents": [{"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 13}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Urinary Tract Infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 13}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 13}]}, {"term": "Muscle Contractions Involuntary", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Oropharyngeal Pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}, {"term": "Rhinitis Allergic", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 12.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 13}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 13}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Netherlands"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10293", "name": "Inflammation", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}